RNA
sequencing is a genomic approach for the identification and quantification
analysis of RNA molecules with the ultimate aim of studying cellular responses
from a biological sample. The advent of RNA sequencing had fueled several
innovations in the medical sector, by facilitating other techniques (that
utilize RNA sequencing) such as single nucleotide polymorphisms identification,
RNA editing, transcriptional profiling and differential gene expression
analysis.
RNA
sequencing offers massive diagnostic utility in terms of rare diseases, which
ranges from rare muscular disorders to mitochondrial diseases such as
mitochondrial depletion syndrome, Leigh’s syndrome, and Kearns-Sayre syndrome,
among others. RNA sequencing is an emerging technique to assess progression of
different rare diseases. It aids medical professionals to understand various
genes linked with specific rare diseases, thereby offering specific treatment
for patients.
The rise in
the discovery of genes associated with rare diseases coupled with the declining
cost of genome sequencing is anticipated to enhance research in the rare
disease segment. This is likely to support sequencing, particularly RNA
sequencing, in the upcoming years.
Based on
the market intelligence published by BIS Research, titled “Global RNA Sequencing Market - Analysis and Forecast, 2019-2028”,
the market is expected grow at a significant CAGR of 14.21% during the forecast
period, 2019-2028. This growth is driven by factors including increasing
adoption of personalized medicine due to decreasing cost of sequencing and increasing
utility in predictive biomarkers and therapeutic response research.
Further,
amongst the various applications of the RNA sequencing, including drug
discovery, translation medicine, diagnostics, and other, the drug discovery
segment emerges as a prominent segment. The segment contributed approximately 44.50%
share in 2018 and is expected to cover a significant share in the application
segment in 2028. This segment is driven by the increase in use of RNA
sequencing to modify drugs to suit the requirements of a specific patient owing
to the incorporation of precision medicine.
In the RNA
sequencing segment, there are several needs that are yet to be addressed by the
stakeholders present in the market. These needs are related to shortage of skilled
professionals in the field of bioinformatics and genomics. To fulfil this shortage
of skilled professionals, regulations for quality analysis and interpretation
of sequencing results are required to be established.
Comments
Post a Comment